This stock continues to bewilder me.Great div yield, low PE, consistent profit growth and still a poor share price.Same as Indigo.
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress